Future of Bispecifics and CAR T in R/R MM

Video content above is prompted by the following:

Future of Bispecifics and CAR T in R/R MM:

The treatment landscape for R/R MM is evolving, with CAR T therapies and bispecific antibodies emerging as key modalities:

• CAR T Therapy: Anitocabtagene autoleucel adds to the growing body of evidence supporting personalized, deep, and durable responses in R/R MM, although accessibility and manufacturing time remain challenges.
• Bispecific Antibodies: Off-the-shelf alternatives offer flexibility and repeated dosing advantages, with ongoing trials optimizing sequencing and combination strategies.

Future research will focus on sequencing, combination approaches, and bridging strategies to enhance outcomes and accessibility in R/R MM treatment.